diabetic ketoacidosis, pregnancy, severe infection, serum potassium levels 45.0 mequiv l À1 , serum Cr levels 43.0 mg per 100 ml, SBP 4180 mm Hg and/or DBP 4120 mm Hg. Previous treatment with other hypoglycemic agents or insulin injection continued with the same dose throughout the study. This study was approved by the Ethical Committee of Gunma University Hospital. Informed consent was obtained from all the patients. All patients were followed in our hospital until the end of this study.
The SBP and DBP were measured by automatic sphyngnomanometer (HEM-7051T, OMRON corporation, Kyoto, Japan) at home after awaking in the morning, and the patients reported the results on the visit to the hospital. Urine specimen was also collected after measuring home blood pressure in the early morning on the same day visiting to the hospital.
All patients were randomly divided by using a closed envelope system into two groups; patients received candesartin cilexetil after breakfast (A group; n¼12) and after dinner (P group; n¼13). Initial dose of candesartin cilexetil was 4-8 mg day À1 , and increased to the maximal dose of 12 mg day À1 according to the results of self-monitored home blood pressure levels after awaking in the early morning. Self-monitored home blood pressure and urine excretion of albumin at 12 weeks after the start of the treatment was compared with those at baseline.
Plasma glucose levels and urinary excretion of albumin were measured by using automatic analyzer with glucose oxidase method and turbidimetric immunoassay, respectively. Glycosylated Hb A 1c levels were measured by the standardized high-performance liquid chromatography method (High Auto A 1c HA8150; ARKRAY Inc., Kyoto, Japan; normal range: 4.3-5.8%).
All data represent mean±s.e.m. The statistical analysis was performed by analysis of variance, followed by Student's t-test for the individual difference of the means. To compare the difference of chronological change of the data, paired t-test was used.
The average of final daily dose of candesartin cilexetil at 12-week was 7.0 ± 1.4 mg in A group, 7.1 ± 1.1 mg in P group. Home systolic blood pressure decreased from 154.0±7.5 to 139.8±5.4 mm Hg in A group, and decreased from 153.4 ± 7.4 to 130.8±7.0 mm Hg in P group. As shown in Figure 1 , the percentage of the reduction of SBP (D%SBP) was significantly (Po0.05) higher in P group (82.7 ± 2.2%) than A group (91.5±3.4%), whereas there was no difference in the reduction of DBP (D%DBP) between both groups (P¼0.198).
The urine albumin index (UAI) decreased from 564.9.0 ± 214.2 mg g À1 Cr to 541.8 ± 239.2 mg g À1 Cr in A group, and decreased from 522.1±431.6 mg g À1 Cr to 352.3±300.7 mg g À1 Cr in P group. The improvement of UAI (D%UAI), measured at the early morning, was significantly (Po0.03) higher in P group (51.5±9.1%) than A group (97.6 ± 15.2%) (Figure 1 ). There were no significant changes by candesartin cilexetil administration for 12 weeks in body weight, postprandial plasma glucose and Hb A 1c levels in both groups.
We have first shown that candesartin administration time difference causes different influences on SBP measured at home after awaking in the morning and urine albumin excretion collected at home in the morning. The optimal dose of candesartan is 16 mg daily for renoprotection, as reflected by short-term reduction of albuminuria in 24-h urine samples, in hypertensive type 2 diabetic patients with nephropathy. 8 However, low-dose candesartan can also prevent early kidney damage in type 2 diabetic patients with mildly higher blood pressure independently of its hypotensive action. 9 Candesartan cilexetil has been also reported to show a dose-related reduction in proteinuria after 12 weeks of treatment, and candesartin cilexetil has been thought to be useful in reducing proteinuria in diabetic patients. 10 In an earlier study, 5.8% reduction of albuminuria was found, in contrast to 32.2% increase in the placebo group, and a 0.8% increase in the 2 mg group. In this study, the average of final daily dose of candesartin cilexetil at 12-week was about 7 mg in both group. Urine samples were collected in the early morning, and 48.5% reduction of UAI was found in P group, in contrast to 2.4% reduction in A group. It was indicated that candesartin cilexetil had better be administered in the evening, resulting in the effective reduction of urine albumin excretion with significantly potent hypotensive effect in the early morning. However, the degree of %SBP appears to be dissociated from the degree of the reduction of UAI. The observed improvement of urine albumin excretion may be attributable to both antihypertensive effects and direct effects on the renal hemodynamics of candesartin cilexetil. There may be a difference in the effects of candesartan cilexetil on the systemic circulation and renal hemodynamics. However, further studies including ambulatory blood pressure monitoring for more than 24 h should be necessary to finally explain the dissociation, as this study examined only changes of home blood pressure in the early morning. It is supposed that diabetic patients with nephropathy had better take ARB in the evening to reduce morning hypertension and albuminuria after awaking in the morning, although further studies should be necessary to determine if the improvement of the UAI in the spot urine collection after awaking can contribute to the delay of the development to end-stage renal disease.
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Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Japan E-mail: hshimizu@showa.gunma-u.ac.jp Figure 1 Changes of self-monitored home systolic blood pressure (SBP), diastolic blood pressure (DBP) and urine albumin index (UAI) after awaking in the early morning after 12-week candesartin cilexetil administration after the breakfast (A) and dinner (P). The percentage of change in each parameter was calculated by dividing 12-week value by its baseline value. *Po0.05 vs. A group.
